Journal articles: 'Antineoplastic agents'

1

Carlson, Patricia A. "Antineoplastic agents." Critical Care Nursing Quarterly 18, no. 4 (February 1996): 1–15. http://dx.doi.org/10.1097/00002727-199602000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Menta, Ernesto, and Manlio Palumbo. "Novel antineoplastic agents." Expert Opinion on Therapeutic Patents 7, no. 12 (December 1997): 1401–26. http://dx.doi.org/10.1517/13543776.7.12.1401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Menta, Ernesto, and Manlio Palumbo. "Antineoplastic agents 1998." Expert Opinion on Therapeutic Patents 8, no. 12 (December 1998): 1627–72. http://dx.doi.org/10.1517/13543776.8.12.1627.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pettit, G. R., Y. Kamano, R. Aoyagi, C. L. Herald, D. L. Doubek, J. M. Schmidt, and J. J. Rudloe. "Antineoplastic agents 100." Tetrahedron 41, no. 6 (January 1985): 985–94. http://dx.doi.org/10.1016/s0040-4020(01)96466-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bukowski, Ronald M. "Novel antineoplastic agents." Current Oncology Reports 2, no. 1 (January 2000): 9–10. http://dx.doi.org/10.1007/s11912-000-0004-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hong, Samuel J., Edward C. Li, Linda M. Matusiak, and Glen T. Schumock. "Spending on Antineoplastic Agents in the United States, 2011 to 2016." Journal of Oncology Practice 14, no. 11 (November 2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of January 1, 2011, to December 31, 2016. Actual expenditures were totaled by health care sector and calendar year, then adjusted for medical-cost inflation to 2016 dollars. Growth was calculated as the percentage increase from the previous year. Results: Total expenditures of antineoplastic agents across all channels grew from $26.8 billion in 2011 to $42.1 billion in 2016. Antineoplastic spending increased 12.2% in 2016 (compared with the previous year), followed by 15.6% in 2015, 13.4% in 2014, 6.3% in 2013, and 0.4% in 2012. Throughout the study period, 96.5% of total antineoplastic expenditures occurred within clinics, mail-order pharmacies, nonfederal hospitals, and retail pharmacies. Conclusion: Antineoplastic expenditures are expected to increase because of continuing development and approval of costly targeted cancer therapies. Cost containment and utilization management strategies must be balanced so as not to restrict access or disrupt innovation. Future policies should focus on ensuring safe and appropriate use of antineoplastics while balancing long-term drug costs.

7

DOLL, DONALD C., Q. SCOT RINGENBERG, and JOHN W. YARBRO. "Antineoplastic Agents and Pregnancy." Obstetrical & Gynecological Survey 45, no. 6 (June 1990): 376. http://dx.doi.org/10.1097/00006254-199006000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 605. Isoquinstatins." Journal of Natural Products 81, no. 3 (September 19, 2017): 451–57. http://dx.doi.org/10.1021/acs.jnatprod.7b00352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hussain, M. A. ha, A. N. toinette J. Wozniak, and M. A. rk B. Edelstein. "Neurotoxicity of antineoplastic agents." Critical Reviews in Oncology/Hematology 14, no. 1 (February 1993): 61–75. http://dx.doi.org/10.1016/1040-8428(93)90006-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Castells, M. "Hypersensitivity to Antineoplastic Agents." Current Pharmaceutical Design 14, no. 27 (September 1, 2008): 2892–901. http://dx.doi.org/10.2174/138161208786369803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Fernandez, F. "Psychotoxicity from antineoplastic agents." Journal of Clinical Oncology 5, no. 2 (February 1987): 319–20. http://dx.doi.org/10.1200/jco.1987.5.2.319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Yamashiro, Yoshiko, Yoshikazu Fukuoka, Akira Yotsuji, Takashi Yasuda, Isamu Saikawa, and Yasushi Ueda. "Interactions of antimicrobial agents and antineoplastic agents." Journal of Antimicrobial Chemotherapy 18, no. 6 (1986): 703–8. http://dx.doi.org/10.1093/jac/18.6.703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Melamed, Andra J., and Michael L. Kleinberg. "Handling Considerations for Cancer Chemotherapeutic Agents." Drug Intelligence & Clinical Pharmacy 22, no. 3 (March 1988): 247–51. http://dx.doi.org/10.1177/106002808802200317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Since the introduction of antineoplastic agents in the 1940s, there have been reports of the effects of these agents on workers who have had prolonged contact with them. The Regional Oncology Drug Information Center (RODIC) at Memorial Sloan-Kettering Cancer Center receives numerous inquiries nationwide regarding our policies and procedures for handling antineoplastic agents. In August 1987, RODIC conducted a computerized literature search on the handling of antineoplastic agents and the risks to hospital employees coming in contact with these agents. We used the MEDLINE system from 1966 to the present, limiting the search to English-language articles. This article provides a comprehensive bibliography on the handling of antineoplastic agents.

14

Garcia, Gwenalyn, and Jean Paul Atallah. "Antineoplastic agents and thrombotic microangiopathy." Journal of Oncology Pharmacy Practice 23, no. 2 (June 23, 2016): 135–42. http://dx.doi.org/10.1177/1078155216628324.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.

15

Sutton, Karen, Tara B. Sanft, Tish M. Knobf, and Izuchukwu K. Ibe. "Musculoskeletal Effects of Antineoplastic Agents." Journal of the American Academy of Orthopaedic Surgeons 27, no. 22 (November 2019): 834–39. http://dx.doi.org/10.5435/jaaos-d-17-00713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

PATTERSON, WILLIAM B. "Occupational Hazard from Antineoplastic Agents." Annals of Internal Medicine 103, no. 6_Part_1 (December 1, 1985): 965. http://dx.doi.org/10.7326/0003-4819-103-6-965_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Graeve, Catherine Utecht, Patricia Marie McGovern, Bruce Alexander, Timothy Church, Andrew Ryan, and Martha Polovich. "Occupational Exposure to Antineoplastic Agents." Workplace Health & Safety 65, no. 1 (October 7, 2016): 9–20. http://dx.doi.org/10.1177/2165079916662660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Approximately 8 million health care workers are unnecessarily exposed to highly toxic drugs used to treat cancer; antineoplastic drugs can contribute to negative health effects for these workers. The drugs have been detected in the urine of workers and on the floors and counters of worksites. Safety precautions that could reduce the risk of exposure are underutilized. This cross-sectional study of 163 oncology health care workers used a survey to measure workplace and individual factors, and environmental sampling to measure surface contamination. The study objective was to identify potential exposures to antineoplastic drugs and factors influencing safety behavior. Personal protective equipment (PPE) use was lower than recommended; unit of employment was significantly associated with PPE use. Chemical residue from antineoplastic drugs was found, revealing potential exposures. Workplace safety must be a higher organizational priority. The contamination of common work areas where PPE use is not expected was of utmost concern.

18

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu, and Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents." American Journal of Clinical Oncology 26, no. 2 (April 2003): 121–23. http://dx.doi.org/10.1097/00000421-200304000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Shahab, Nasir, Syed Haider, and Donald C. Doll. "Vascular Toxicity of Antineoplastic Agents." Seminars in Oncology 33, no. 1 (February 2006): 121–38. http://dx.doi.org/10.1053/j.seminoncol.2005.11.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (February 1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information is submitted to the FDA for their review and approval for marketing. Prior to that approval, the FDA may approve broader distribution of the drug for specific indications under a Treatment Investigational New Drug (IND) or the National Cancer Institute's (NCI) group C mechanism. Pharmacists can play a unique role during development of the Treatment IND by contributing to design of the protocol and screening patient qualifications. The investigator of the clinical trial has responsibility for the conduct of the clinical trial and must comply with FDA regulations and sponsor policies. This is a US government work. There are no restrictions on its use.

21

Chitambar, Christopher R. "Gallium compounds as antineoplastic agents." Current Opinion in Oncology 16, no. 6 (November 2004): 547–52. http://dx.doi.org/10.1097/01.cco.0000142071.22226.d2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Hamnvik, O. P. R., P. R. Larsen, and E. Marqusee. "Thyroid Dysfunction from Antineoplastic Agents." JNCI Journal of the National Cancer Institute 103, no. 21 (October 18, 2011): 1572–87. http://dx.doi.org/10.1093/jnci/djr373.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Grangé, Steven, and Paul Coppo. "Thrombotic microangiopathies and antineoplastic agents." Néphrologie & Thérapeutique 13 (April 2017): S109—S113. http://dx.doi.org/10.1016/j.nephro.2017.01.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 606. The Betulastatins." Journal of Natural Products 81, no. 3 (January 5, 2018): 458–64. http://dx.doi.org/10.1021/acs.jnatprod.7b00536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 607. Emetine Auristatins." Journal of Natural Products 83, no. 5 (April 23, 2020): 1571–76. http://dx.doi.org/10.1021/acs.jnatprod.0c00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pettit, G. R., S. B. Singh, A. Goswami, and R. A. Nieman. "Antineoplastic agents 157. Quassia kerstingII1." Tetrahedron 44, no. 11 (January 1988): 3349–54. http://dx.doi.org/10.1016/s0040-4020(01)85969-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pettit, George R., Venkatswamy Gaddamidi, Delbert L. Herald, Sheo Bux Singh, Gordon M. Cragg, Jean M. Schmidt, Fred E. Boettner, M. Williams, and Yoneo Sagawa. "Antineoplastic Agents, 120. Pancratium littorale." Journal of Natural Products 49, no. 6 (November 1986): 995–1002. http://dx.doi.org/10.1021/np50048a005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Pettit, George R., Gordon M. Cragg, Sheo Bux Singh, James A. Duke, and Dennis L. Doubek. "Antineoplastic Agents, 162. Zephyranthes candida." Journal of Natural Products 53, no. 1 (January 1990): 176–78. http://dx.doi.org/10.1021/np50067a026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Rogers, Bonnie. "Antineoplastic Agents Action and Toxicities." AAOHN Journal 34, no. 11 (November 1986): 530–38. http://dx.doi.org/10.1177/216507998603401104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Bodet, C. A., J. H. Jorgensen, and D. J. Drutz. "Antibacterial activities of antineoplastic agents." Antimicrobial Agents and Chemotherapy 28, no. 3 (September 1, 1985): 437–39. http://dx.doi.org/10.1128/aac.28.3.437.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Pettit, George R., Noeleen Melody, Michael Simpson, Michael Thompson, Delbert L. Herald, and John C. Knight. "Antineoplastic Agents 500. Narcistatin†,1." Journal of Natural Products 66, no. 1 (January 2003): 92–96. http://dx.doi.org/10.1021/np020225i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu, and Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents." American Journal of Clinical Oncology 26, no. 2 (April 2003): 121–23. http://dx.doi.org/10.1097/01.coc.0000017088.74592.96.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Weiss, Raymond B., and James R. Baker. "Hypersensitivity reactions from antineoplastic agents." Cancer and Metastasis Reviews 6, no. 3 (November 1987): 413–32. http://dx.doi.org/10.1007/bf00144273.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Borch, Richard F., and Thomas J. Montine. "Renal toxicity of antineoplastic agents." Toxicology Letters 53, no. 1-2 (September 1990): 93–96. http://dx.doi.org/10.1016/0378-4274(90)90100-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Johnson, Candace S. "Modulation of chemotherapy antineoplastic agents with biologic agents." Current Opinion in Oncology 4, no. 6 (December 1992): 1108. http://dx.doi.org/10.1097/00001622-199212000-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Hall, Amy L., Paul A. Demers, George Astrakianakis, Calvin Ge, and Cheryl E. Peters. "Estimating National-Level Exposure to Antineoplastic Agents in the Workplace: CAREX Canada Findings and Future Research Needs." Annals of Work Exposures and Health 61, no. 6 (June 8, 2017): 656–58. http://dx.doi.org/10.1093/annweh/wxx042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

AbstractObjectives:Occupational exposure to antineoplastic agents occurs in various environments and is associated with increased cancer risk and adverse reproductive outcomes. National-level information describing the location and extent of occupational exposure to antineoplastic agents is unavailable in Canada and most other countries. CAREX Canada aimed to estimate the prevalence and relative levels of occupational exposures to antineoplastic agents across work setting, occupation, and sex.Methods:‘Exposure’ was defined as any potential for worker contact with antineoplastic agents. Baseline numbers of licensed workers were obtained from their respective professional bodies. For unlicensed workers, Census data or data extrapolated from human resources reports (e.g., staffing ratios) were used. Prevalence was estimated by combining population estimates with exposure proportions from peer-reviewed and grey literature. Exposure levels (classified as low, moderate, and high) by occupation and work setting were estimated qualitatively by combining estimates of contact frequency and exposure control practices.Results:Approximately 75000 Canadians (0.42% of the total workforce) are estimated as occupationally exposed to antineoplastic agents; over 75% are female. The largest occupational group exposed to antineoplastic agents is community pharmacy workers, with 30200 exposed. By work setting, 39000 workers (52% of all exposed) are located in non-hospital settings; the remaining 48% are exposed in hospitals. The majority (75%) of workers are in the moderate exposure category.Conclusions:These estimates of the prevalence and location of occupational exposures to antineoplastic agents could be used to identify high-risk groups, estimate disease burden, and target new research and prevention activities. The limited secondary data available for developing these estimates highlights the need for increased quantitative measurement and documentation of antineoplastic agent contamination and exposure, particularly in work environments where use is emerging.

37

&NA;. "Antineoplastic agents can cause allergic reactions." Reactions Weekly &NA;, no. 428 (November 1992): 4. http://dx.doi.org/10.2165/00128415-199204280-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Pharmacokinetic drug interactions with antineoplastic agents." Drugs & Therapy Perspectives 5, no. 9 (May 1995): 12–14. http://dx.doi.org/10.2165/00042310-199505090-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

BATRA, JANENDRA K., CHII M. LIN, ERNEST HAMEL, LEONARD JURD, and LARRY J. POWERS. "New Antineoplastic Agents with Antitubulin Activity." Annals of the New York Academy of Sciences 466, no. 1 Dynamic Aspec (June 1986): 785–87. http://dx.doi.org/10.1111/j.1749-6632.1986.tb38459.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

McDiarmid, Melissa, and Thomas Egan. "Acute Occupational Exposure to Antineoplastic Agents." Journal of Occupational and Environmental Medicine 30, no. 12 (December 1988): 984–87. http://dx.doi.org/10.1097/00043764-198812000-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Dimopoulou, I., A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos. "Pulmonary toxicity from novel antineoplastic agents." Annals of Oncology 17, no. 3 (March 2006): 372–79. http://dx.doi.org/10.1093/annonc/mdj057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Delitheos, A., I. Karavokyros, and E. Tiligada. "Response ofSaccharomyces cerevisiaestrains to antineoplastic agents." Journal of Applied Bacteriology 79, no. 4 (October 1995): 379–83. http://dx.doi.org/10.1111/j.1365-2672.1995.tb03151.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Phillips, Nancy C. "The Safe Handling of Antineoplastic Agents." Journal of Pharmacy Technology 1, no. 1 (January 1985): 19–24. http://dx.doi.org/10.1177/875512258500100108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Davis, Lisa E. "Long-Term Complications of Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 2 (April 1991): 131–50. http://dx.doi.org/10.1177/089719009100400208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Hercbergs, A. A., D. Garfield, O. Ashur-Fabian, and P. J. Davis. "Re: Thyroid Dysfunction from Antineoplastic Agents." JNCI Journal of the National Cancer Institute 104, no. 5 (January 30, 2012): 422–23. http://dx.doi.org/10.1093/jnci/djs011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

P. Torchilin, Vladimir, Leonid Z. Iakoubov, and Zeev Estrov. "Antinuclear autoantibodies as potential antineoplastic agents." Trends in Immunology 22, no. 8 (August 2001): 424–27. http://dx.doi.org/10.1016/s1471-4906(01)01984-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Wiebe, Valerie J., and Pirkko E. H. Sipila. "Pharmacology of antineoplastic agents in pregnancy." Critical Reviews in Oncology/Hematology 16, no. 2 (April 1994): 75–112. http://dx.doi.org/10.1016/1040-8428(94)90043-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Markman, Maurie. "Toxicities of the platinum antineoplastic agents." Expert Opinion on Drug Safety 2, no. 6 (November 2003): 597–607. http://dx.doi.org/10.1517/14740338.2.6.597.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Polovich, Martha. "Minimizing Occupational Exposure to Antineoplastic Agents." Journal of Infusion Nursing 39, no. 5 (2016): 307–13. http://dx.doi.org/10.1097/nan.0000000000000183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lazo, John S. "Endothelial injury caused by antineoplastic agents." Biochemical Pharmacology 35, no. 12 (June 1986): 1919–23. http://dx.doi.org/10.1016/0006-2952(86)90720-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Antineoplastic agents'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles